FAMILY

"Running in the FAMILY – Understanding and predicting the intergenerational transmission of mental illness"

Grant Agreement number: 101057529

Deliverable 5.12 Report on the status of posting results clinical study POBI-CHUV

Workpackage:	WP 5
Task:	Task 5.1
Due Date:	30th September 2025 (M36)
Actual Submission Date:	30th September 2025 (M36)
Project Dates:	Project Start Date: October 01, 2022 Project Duration: 60 months
Responsible partner:	Partner 15 CHUV
Responsible author:	Caroline Van der Leur
Email:	Caroline.Vandeleur@chuv.ch
Contributors:	

Project funded by the European Commission within HORIZON-HLTH-2021-STAYHLTH-01-02: Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patients'		
Dissemination Level		
PU	Public — fully open (automatically posted online)	X
SEN	Sensitive — limited under the conditions of the Grant Agreement	

Document History:

Version	Date	Changes	From	Review
V1.0	25/09/2025	Draft version	Caroline Van der Leur	Juliane Dittrich
V1.0	30/09/2025	Final version	Caroline Van der Leur	Neeltje van Haren

Open Issues - not applicable

SUMMARY

According to the definition of Deliverable 5.12 this document provides an overview of the status of posting results for clinical study POBI-CHUV.

TABLE OF CONTENTS

1 SUMMARY OF POSTING STUDY RESULTS FOR CLINICAL STUDY POBI-CHUV

1.1 Recruitment progress

At the DP-CHUV, we recruited both parents and offspring on whom information was lacking to form the DUOs and TRIOs requested for the FAMILY project.

This document describes the end of the recruitment period for POBI-CHUV as of September 30th, 2025.

Overview of the number of recruited participants

Status per 30.09.2025

	Lausanne-Geneva cohort
Total to be recruited	3519
Included	414
Scheduled for inclusion	0
Excluded for various reasons	3105*
To be recruited (%)	0

*The high number is expected and largely attributable to our recruitment of population-based controls and not to the families of patients with mood disorders. Indeed, we have recruited a very large number of controls with offspring and partially with spouses who had psychopathological investigations, but it was difficult to motivate them to come to a physical investigation with blood probes and MRI exams. In addition, many participants met exclusionary criteria for MRI.

Problems in recruitment

No problems, we were well in advance of the schedule.

In the next 6 months, we will process the brain scans, complete the remaining genotyping of the parents and offspring on whom we have collected blood samples and quality check the collected data. We aim to complete this process by Spring 2026.

Conclusion

The table below shows the overview of the recruitment status of the 4 clinical cohorts. In the final periodic report, we will be able to report results of the planned tasks.

	BASYS-Barcelona	BASYS-Madrid	BRIDGE-Rotterdam	Lausanne-Geneva cohort
Total to be recruited	316	254*	498	3519
Included	194	131	153	414
Excluded for various reasons	107**	120**	307**	3105***
To be recruited (%)	15 (4.75%)	3 (0.01%)	38 (7.63%)	0

*Including previously non-included offspring **Excluded: e.g., contra-indication MRI, no current contact details, passed away. Refused: e.g., travel distance, no time or interest. ***The high number is expected and largely attributable to our recruitment of population-based controls and not to the families of patients with mood disorders. Indeed, we have recruited a very large number of controls with offspring and partially with spouses who had psychopathological investigations, but it was difficult to motivate them to come to a physical investigation with blood probes and MRI exams. In addition, many participants met exclusionary criteria for MRI.

ACKNOWLEDGEMENT

Funded by the European Union, the Swiss State Secretariat for Education, Research and Innovation (SERI) and the UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee'. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union, or the European Health and Digital Executive Agency (HADEA), the SERI or the UK Research and Innovation (UKRI). Neither the European Union nor the granting authorities can be held responsible for them.